Key result
During pre-maintenance chemotherapy for pediatric ALL, obesity significantly increased the risk of treatment-requiring hypertension (OR 3.90; 95% CI 1.19-12.76; P=0.02).
Why the study?
Does obesity increase the risk of adverse events during pre-maintenance chemotherapy in pediatric patients with acute lymphoblastic leukemia?
Cohort (n=155)
No
Does obesity increase the risk of adverse events during pre-maintenance chemotherapy in pediatric patients with acute lymphoblastic leukemia?
Odds Ratio: 3.9 (95% CI 1.19–12.76)
Absolute Event Rate: 17.5% vs 6.1%
p-value: p=0.02
In pediatric patients with acute lymphoblastic leukemia, obesity significantly increases the risk of adverse events including hypertension, hyperglycemia, and febrile neutropenia during pre-maintenance chemotherapy.
May support closer hypertension monitoring in obese pediatric ALL patients; hypothesis-generating and requires prospective validation.
PURPOSE: Obesity correlates with adverse events (AEs) in children with acute myelogenous leukemia and during maintenance therapy for acute lymphoblastic leukemia (ALL). Less is known about AEs in obese ALL patients during pre-maintenance chemotherapy. We evaluated the relationship between obesity (body mass index (BMI) ≥ 95th percentile) and AEs during pre-maintenance chemotherapy in pediatric patients with ALL. METHODS: One hundred fifty-five pediatric ALL patients diagnosed at a single institution between 2006 and 2012 were retrospectively evaluated for infections, treatment-requiring hypertension, insulin-requiring hyperglycemia, pancreatitis, pediatric intensive care unit admissions, sepsis, febrile neutropenia (FN) admissions, thrombosis, hepatotoxicity, and nephrotoxicity. Univariate and multivariable analyses compared proportions of obese versus nonobese patients experiencing AEs. RESULTS: AEs occurring significantly more frequently in obese patients by univariate analysis included treatment-requiring hypertension (17.5% vs 6.1%; OR, 3.27; 95% CI, 1.1-10.0, P = 0.0497) and insulin-requiring hyperglycemia (25.0% vs 11.3%; OR, 2.62; 95% CI, 1.04-6.56, P = 0.04). Obese patients had greater incidence rates for recurrent admission-requiring infections (incidence rate ratio (IRR) 1.64; 95% CI, 1.08-2.48, P = 0.02) and recurrent FN admissions (IRR, 1.53; 95% CI, 1.10-2.12, P = 0.01). Accounting for combined age and NCI risk status, obesity was a risk factor for treatment-requiring hypertension (OR, 3.90; 95% CI, 1.19-12.76, P = 0.02), insulin-requiring hyperglycemia (OR, 3.92; 95% CI, 1.39-11.05, P = 0.01), and FN admission (OR, 2.92; 95% CI, 1.27-6.73, P = 0.01). CONCLUSIONS: During pre-maintenance chemotherapy for ALL, obesity is a risk factor for the development of hypertension, hyperglycemia, and FN admissions. This research provides implications for augmented preventive and supportive care guidelines in obese ALL patients.
No takes yet. Share an insight, caveat, or question.
Meenan et al. (2018) conducted a cohort in Acute lymphoblastic leukemia (n=155). Obesity (BMI ≥ 95th percentile) vs. Nonobese patients was evaluated on Treatment-requiring hypertension (adjusted for age and NCI risk status) (OR 3.90, 95% CI 1.19-12.76, p=0.02). During pre-maintenance chemotherapy for pediatric ALL, obesity significantly increased the risk of treatment-requiring hypertension (OR 3.90; 95% CI 1.19-12.76; P=0.02).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: